Novo Nordisk shares jumped 8% Monday after Hims & Hers stated it should pull its copycat weight-loss pill off the market.
Novo Nordisk, maker of Wegovy, and the U.S. Meals and Drug Administration had threatened authorized motion towards Hims & Hers, which introduced over the weekend it will not promote the pill.
“Since launching the compounded semaglutide pill on our platform, we have had constructive conversations with stakeholders throughout the business,” Hims & Hers posted on social media on Saturday.
“Consequently, we’ve got determined to cease providing entry to this therapy. We stay dedicated to the hundreds of thousands of People who rely upon us for entry to protected, reasonably priced, and customized care.”
It is a breaking information story. Please refresh for updates.
Source link
#Novo #Nordisk #pops #Hims #pulls #copycat #weightloss #pill
